Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Four years after the Covid pandemic started in North America, demand for Covid vaccines is weakening considerably. In ...

Moderna’s stock has seen an extended downtrend since peaking above $480 in late 2021. After crashing to below $70 in November last year, the stock experienced a strong medium-term rally that took it ...

Moderna shares drop as company plans to reduce annual R&D expenses by $1.1B starting in 2027, focusing on portfolio ...

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending ...

DPX™-RSV for Respiratory Syncytial Virus, DPX™+peanut antigen for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© "neoantigen" tumor ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Moderna shares drop as company plans to reduce annual R&D expenses by $1.1B starting in 2027, focusing on portfolio prioritization and cost efficiencies.

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...